Gloria Vigliani
Biogen Idec
10 Papers
Gloria Vigliani is an academic researcher from Biogen Idec. The author has contributed to research in topics: Medicine & Daptomycin. The author has an hindex of 9, co-authored 10 publications. Previous affiliations of Gloria Vigliani include Cubist Pharmaceuticals.
Chat about Author
Papers
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Vance G. Fowler,Helen W. Boucher,G. Ralph Corey,Elias Abrutyn,Adolf W. Karchmer,Mark E. Rupp,Donald P. Levine,Henry F. Chambers,Francis P. Tally,Gloria Vigliani,Christopher H. Cabell,Arthur Stanley Link,Ignace DeMeyer,Scott G. Filler,Marcus J. Zervos,Paul P. Cook,Jeffrey Parsonnet,Jack M. Bernstein,Connie S. Price,Graeme N. Forrest,Gerd Fätkenheuer,Marcelo Gareca,Susan J. Rehm,Hans Reinhardt Brodt,Alan D. Tice,Sara E. Cosgrove +25 more
TL;DR: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu,Jerry S. Powell,Margaret V. Ragni,Pratima Chowdary,Neil C. Josephson,Ingrid Pabinger,H. Hanabusa,Naresh Gupta,Roshni Kulkarni,Patrick F. Fogarty,David J. Perry,Amy D. Shapiro,K. John Pasi,Shashikant Apte,Ivan Nestorov,Haiyan Jiang,Shuanglian Li,Srividya Neelakantan,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Nigel Dodd,Karen Nugent,Gloria Vigliani,Alvin Luk,Aoife Brennan,Glenn F. Pierce +27 more
TL;DR: In this paper, the authors evaluated the safety, efficacy, and pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥12 years with severe hemophilia A.
411
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell,K. John Pasi,Margaret V. Ragni,Margareth C. Ozelo,Leonard A. Valentino,Johnny Mahlangu,Neil C. Josephson,D. J. Perry,Marilyn J. Manco-Johnson,Shashikant Apte,Ross I. Baker,Godfrey Chi-Fung Chan,Nicolas Novitzky,Raymond S.M. Wong,Snejana Krassova,G. Allen,Haiyan Jiang,Alison Innes,Shuanglian Li,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Karen Nugent,Gloria Vigliani,Aoife Brennan,Alvin Luk,Glenn F. Pierce +27 more
- 11 Dec 2013
TL;DR: Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B, mostly consistent with those expected in the general population of patients withhemophilia.
Initial Low-Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic
Sara E. Cosgrove,Gloria Vigliani,Marilyn Campion,Vance G. Fowler,Elias Abrutyn,G. Ralph Corey,Donald P. Levine,Mark E. Rupp,Henry F. Chambers,Adolf W. Karchmer,Helen W. Boucher +10 more
TL;DR: Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.
323
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
Susan J. Rehm,Helen W. Boucher,Donald P. Levine,Marilyn Campion,Barry I. Eisenstein,Barry I. Eisenstein,Gloria Vigliani,G. Ralph Corey,Elias Abrutyn +8 more
TL;DR: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacteraemia or right-sided endocarditis and success rates were lower in the elderly (≥75 years); the clinical course of several patients may have been influenced by lack of surgical intervention.